EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes ( TRIPLE ‐ AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial

Nam Hoon Kim iD, Jun Sung Moon iD, Yong-Ho Lee iD, Ho Chan Cho, Soo Heon Kwak, Soo Lim iD, Min Kyong Moon iD, Dong-Lim Kim, Tae Ho Kim, Eunvin Ko, Juneyoung Lee, Sin Gon Kim iD

Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3642-3652

DOI: 10.1111/dom.15705 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.06.2024. Verfasst von Nam Hoon Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Glucosides, Benzhydryl Compounds. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the efficacy and tolerability of an initial triple combination therapy (TCT) compared with conventional stepwise add‐on therapy (SAT) in patients with newly diagnosed type 2 diabetes (T2D). Materials and Methods This multicentre, randomized, 104‐week, open‐label trial randomized 105 patients with drug‐naïve T2D (with HbA1c level ≥ 8.0%, < 11.0%) to the TCT (1000 mg of metformin, 10 mg of dapagliflozin and 5 mg of saxagliptin once daily) or SAT (initiated with metformin, followed by glimepiride and sitagliptin) groups. The primary outcome was the proportion of patients who achieved an HbA1c level of less than 6.5% without hypoglycaemia, weight gain of 5% or higher, or discontinuation of drugs because of adverse events at week 104.

Results

HbA1c reduction from baseline at week 104 was similar between the groups (the least squares mean change was −2.56% in the TCT group vs. –2.75% in the SAT group). The primary outcome was achieved in 39.0% and 17.1% of the TCT and SAT groups, respectively, with a risk difference of 22.0 (95% confidence interval 3.0, 40.8; P = .027). HbA1c level less than 6.5% at week 104 was 46.3% in both the TCT and SAT groups, whereas the incidence of hypoglycaemia, weight gain, or discontinuation of drugs was 16.7% and 62.0% in the TCT and SAT groups, respectively ( P < .001). TCT was well‐tolerated and had fewer adverse events than SAT.

Conclusions

Among newly diagnosed patients with T2D, initial TCT effectively lowered HbA1c levels with higher tolerability and safety than SAT for 104 weeks, suggesting a novel strategy for initial combination therapy in T2D patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminGlucosidesBenzhydryl CompoundsDrug Therapy, CombinationDipeptidesAdamantaneHypoglycemic AgentsGlycated HemoglobinHumansMaleFemaleMiddle AgedAgedTreatment OutcomeHypoglycemiaSulfonylurea CompoundsBlood GlucoseAdultWeight GainSitagliptin Phosphate

Stichwörter der Autor:innen

DPP‐4 inhibitorSGLT2 inhibitorclinical trialglycaemic controltype 2 diabetes

Substanzen

dapagliflozinMetforminsaxagliptinGlucosidesBenzhydryl CompoundsDipeptidesAdamantaneHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Endocrinology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Korea.

ORCID-Profile: Nam Hoon Kim, Jun Sung Moon, Yong-Ho Lee, Soo Lim, Min Kyong Moon, Sin Gon Kim

Zitieren

APA

Kim, N. H., Moon, J. S., Lee, Y. H., Cho, H. C., Kwak, S. H., Lim, S., Moon, M. K., Kim, D. L., Kim, T. H., Ko, E., Lee, J., & Kim, S. G. (2024). Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes ( TRIPLE ‐ AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial. Diabetes, Obesity and Metabolism, 26(9), 3642-3652. https://doi.org/10.1111/dom.15705

Vancouver

Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, et al. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes ( TRIPLE ‐ AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial. Diabetes, Obesity and Metabolism. 2024;26(9):3642-3652. doi:10.1111/dom.15705

BibTeX
@article{Kim2024,
  author = {Kim, Nam Hoon and Moon, Jun Sung and Lee, Yong-Ho and Cho, Ho Chan and Kwak, Soo Heon and Lim, Soo and Moon, Min Kyong and Kim, Dong-Lim and Kim, Tae Ho and Ko, Eunvin and Lee, Juneyoung and Kim, Sin Gon},
  title = {Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes ( TRIPLE ‐ AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {3642--3652},
  doi = {10.1111/dom.15705}
}
Kostenlos starten →